NASDAQ: DRIODariohealth Corp Stock
$1.15-0.06 (-4.96%)
Updated Apr 18, 2024
DRIO Price
$1.15
Fair Value Price
N/A
Market Cap
$33.86M
52 Week Low
$0.68
52 Week High
$4.58
P/E
-0.6x
P/B
0.58x
P/S
2.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.35M
Earnings
-$59.43M
Gross Margin
29.4%
Operating Margin
-291.68%
Profit Margin
-312.1%
Debt to Equity
0.66
Operating Cash Flow
-$30M
Beta
1.15
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DRIO Overview
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DRIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DRIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DRIO is good value based on its book value relative to its share price (0.58x), compared to the US Diagnostics & Research industry average (4.01x)
P/B vs Industry Valuation
DRIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DRIO due diligence checks available for Premium users.
Be the first to know about important DRIO news, forecast changes, insider trades & much more!
DRIO News
Valuation
DRIO fair value
Fair Value of DRIO stock based on Discounted Cash Flow (DCF)
Price
$1.15
Fair Value
$3.51
Undervalued by
67.21%
DRIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DRIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
36.3x
Market
41.33x
DRIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
4.01x
DRIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DRIO's financial health
Profit margin
Revenue
$3.6M
Net Income
-$14.3M
Profit Margin
-428.8%
DRIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DRIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$96.4M
Liabilities
$38.2M
Debt to equity
0.66
DRIO's short-term assets ($47.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DRIO's short-term assets ($47.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DRIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DRIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.3M
Investing
-$83.0k
Financing
$0.0
DRIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DRIO vs Diagnostic & Research Stocks
Dariohealth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.